Ranbaxy's Court Win On Lipitor Generics Leaves Compliance Issues Unanswered
This article was originally published in PharmAsia News
Executive Summary
India's Ranbaxy Laboratories may have been freed to launch a U.S. generic of the world's best-selling drug if it gets U.S. FDA approval, but a court's action allowing it to do so failed to settle several issues roiling within the pharmaceutical industryYou may also be interested in...
UK Sunscreen Claims On ‘Negligible’ Difference In SPF Strengths Don't Add Up
Advertising Standards Authority says Green People Co. misled consumers with claims SPF 30 formulas filter out only 1% less UVB rays than SPF 50, trying to draw a negligible difference between the formulas. The claims appeared in a direct mailer and on the brand’s website in July 2019.
Court Rules More Trial Data Must Be Posted On ClinicalTrials.gov
Plaintiff Peter Lurie, former US FDA associate commissioner, expects results of hundreds of clinical trials of approved drugs will become available under ruling against HHS; co-plaintiff sought eteplirsen study data.
Drug Shortages Loom If Coronavirus Persists In China, Generics Execs Say
Drug shortages will become a bigger issue in a few months if ingredient supply disruptions in China persist, Bernstein analyst Gal concluded from discussions with four generic executives.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports